Hyperion DeFi (NASDAQ:HYPD) Receives Buy Rating from Chardan Capital

Hyperion DeFi (NASDAQ:HYPD)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $7.30 target price on the stock. Chardan Capital’s price target indicates a potential upside of 181.96% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald boosted their target price on shares of Hyperion DeFi from $4.00 to $6.60 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Weiss Ratings raised Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 24th. Finally, Zacks Research raised Hyperion DeFi from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 14th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.95.

Hyperion DeFi Stock Down 0.8%

Shares of NASDAQ:HYPD traded down $0.02 during trading on Tuesday, reaching $2.59. 90,471 shares of the stock were exchanged, compared to its average volume of 438,189. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.97 and a quick ratio of 1.97. Hyperion DeFi has a 1-year low of $2.34 and a 1-year high of $15.00. The stock has a fifty day moving average of $2.96 and a two-hundred day moving average of $3.36. The firm has a market cap of $39.25 million, a price-to-earnings ratio of -0.26 and a beta of 2.53.

Insider Activity

In related news, insider Hyunsu Jung purchased 7,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were bought at an average cost of $3.70 per share, with a total value of $25,900.00. Following the acquisition, the insider owned 1,384,676 shares of the company’s stock, valued at $5,123,301.20. This represents a 0.51% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 7.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Sanctuary Advisors LLC purchased a new stake in Hyperion DeFi during the fourth quarter valued at about $38,000. Nations Financial Group Inc. IA ADV bought a new stake in Hyperion DeFi during the 4th quarter valued at $40,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Hyperion DeFi during the 4th quarter valued at $73,000. State Street Corp purchased a new stake in Hyperion DeFi during the 4th quarter worth about $92,000. Finally, Investment House LLC purchased a new position in Hyperion DeFi during the 4th quarter valued at about $166,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.